Pfizer’s $43 Billion Seagen Takeover Gets EU Merger Review
- European Commission sets Oct. 19 deadline for initial decision
- Seagen is leader in medicine used to help fight cancers
The Seagen headquarters in Bothell, Washington, US.
Photographer: David Ryder/BloombergThis article is for subscribers only.
Pfizer Inc.’s $43 billion takeover of Seagen Inc. faces a European Union review after the companies formally notified the bloc’s merger watchdog.
The European Commission set Oct. 19 as a deadline to complete its initial probe, according to a filing on its website on Friday.